Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Stepwise Basal Insulin Dose Titration Study Using Continuous Subcutaneous Insulin Infusion (CSII) in Oral Antidiabetic Drug-Treated Type 2 Diabetes Mellitus Subjects Followed by a 10-Week Out-Patient Maintenance Phase

NCT00115973 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00115973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00115973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Stepwise Basal Insulin Dose Titration Study Using Continuous Subcutaneous Insulin Infusion (CSII) in Oral Antidiabetic Drug-Treated Type 2 Diabetes Mellitus Subjects Followed by a 10-Week Out-Patient Maintenance Phase
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2005
Completion date
January 31, 2006
Enrollment
71 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

delivery systems, diabetes, diabetes mellitus, type 2